Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 9, 2013, Pages 808-815

  Sciacca, L ^a   Vigneri, R ^a,b   Tumminia, A ^a   Frasca, F ^a   Squatrito, S ^a   Frittitta, L ^a   Vigneri, P ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Humanitas Oncology Center   (Italy)

Author keywords

Carcinogenesis; Hyperglycemia; Hyperinsulinemia; Tumors and diabetes

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; AROMATASE; BIGUANIDE DERIVATIVE; CYTOKINE; ESTROGEN; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GROWTH FACTOR; HEPATOCYTE NUCLEAR FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCRETIN; INSULIN; LEPTIN; METFORMIN; MICRORNA; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; STAT3 PROTEIN; SULFONYLUREA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLORECTAL CANCER; COMORBIDITY; DIABETES MELLITUS; DIABETIC OBESITY; DIABETIC PATIENT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; KIDNEY CANCER; LIVER CELL CARCINOMA; MITOGENESIS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW;

CARCINOGENESIS; HYPERGLYCEMIA; HYPERINSULINEMIA; TUMORS AND DIABETES;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIVER NEOPLASMS; MALE; OBESITY; PANCREAS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84884145031     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.05.006     Document Type: Review

References (64)

1. Vigneri P., Frasca F., Sciacca L., Pandini G., Vigneri R. Diabetes and cancer. Endocrine-Related Cancer 2009 Dec, 16(4):1103-1123.
2. Barone B.B., Yeh H.C., Snyder C.F., Peairs K.S., Stein K.B., Derr R.L., et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. The Journal of the American Medical Association 2008 Dec 17, 300(23):2754-2764.
3. Shikata K., Ninomiya T., Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Science 2013 Jan, 104(1):9-14.
4. Bonovas S., Filioussi K., Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004 Jun, 47(6):1071-1078.
5. Heuson J.C., Legros N., Heimann R. Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Research 1972 Feb, 32(2):233-238.
6. Milazzo G., Sciacca L., Papa V., Goldfine I.D., Vigneri R. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Molecular Carcinogenesis 1997 Jan, 18(1):19-25.
7. Shukla A., Grisouard J., Ehemann V., Hermani A., Enzmann H., Mayer D. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocrine-Related Cancer 2009 Jun, 16(2):429-441.
8. Sciacca L., Cassarino M.F., Genua M., Pandini G., Le Moli R., Squatrito S., et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 2010 Aug, 53(8):1743-1753.
9. Hernandez-Diaz S., Adami H.O. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 2010 May, 53(5):802-808.
10. Gerstein H.C., Bosch J., Dagenais G.R., Diaz R., Jung H., Maggioni A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine 2012 Jul 26, 367(4):319-328.
11. Bolli G.B., Consoli A., Giaccari A. Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? an open debate on the ORIGIN study results. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 2012 Dec, 22(12):1007-1012.
12. Vigneri R., Vigneri P., Frittitta L. Basal insulin and cardiovascular and other outcomes. The New England Journal of Medicine 2012 Nov, 367(18):3-4. 1761-2; author reply.
13. Currie C.J., Poole C.D., Evans M., Peters J.R., Morgan C.L. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2013 Feb, 98(2):668-677.
14. Li C., Zhao G., Okoro C.A., Wen X.J., Ford E.S., Balluz L.S. Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. Adults with diagnosed diabetes: findings from the 2009 behavioral risk factor surveillance system. Diabetes Care 2013 Jan 8.
15. Menting J.G., Whittaker J., Margetts M.B., Whittaker L.J., Kong G.K., Smith B.J., et al. How insulin engages its primary binding site on the insulin receptor. Nature 2013 Jan 10, 493(7431):241-245.
16. Cusi K., Maezono K., Osman A., Pendergrass M., Patti M.E., Pratipanawatr T., et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. The Journal of Clinical Investigation 2000 Feb, 105(3):311-320.
17. Papa V., Pezzino V., Costantino A., Belfiore A., Giuffrida D., Frittitta L., et al. Elevated insulin receptor content in human breast cancer. The Journal of Clinical Investigation 1990 Nov, 86(5):1503-1510.
18. Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 1999 May, 19(5):3278-3288.
19. Cascio S., Bartella V., Auriemma A., Johannes G.J., Russo A., Giordano A., et al. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. Oncogene 2008 Jan 17, 27(4):540-547.
20. Gonzalez-Perez R.R., Xu Y., Guo S., Watters A., Zhou W., Leibovich S.J. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 2010 Sep, 22(9):1350-1362.
21. Stattin P., Bjor O., Ferrari P., Lukanova A., Lenner P., Lindahl B., et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007 Mar, 30(3):561-567.
22. Sieri S., Pala V., Brighenti F., Agnoli C., Grioni S., Berrino F., et al. High glycemic diet and breast cancer occurrence in the Italian EPIC cohort. Nutrition, Metabolism, and Cardiovascular Diseases 2012 Apr 10.
23. Zhou X.H., Qiao Q., Zethelius B., Pyorala K., Soderberg S., Pajak A., et al. Diabetes, prediabetes and cancer mortality. Diabetologia 2010 Sep, 53(9):1867-1876.
24. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009 May 22, 324(5930):1029-1033.
25. Young C.D., Anderson S.M. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Research 2008, 10(1):202.
26. Long Y.C., Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. The Journal of Clinical Investigation 2006 Jul, 116(7):1776-1783.
27. Bhattacharyya S., Sul K., Krukovets I., Nestor C., Li J., Adognravi O.S. Novel tissue-specific mechanism of regulation of angiogenesis and cancer growth in response to hyperglycemia. Journal of the American Heart Association 2012 Dec, 1(6):e005967.
28. Rojas A., Figueroa H., Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 2010 Mar, 31(3):334-341.
29. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 Sep, 52(9):1766-1777.
30. Vigneri P., Frasca F., Sciacca L., Frittitta L., Vigneri R. Obesity and cancer. Nutrition, Metabolism, and Cardiovascular Diseases 2006 Jan, 16(1):1-7.
31. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine 2003 Apr 24, 348(17):1625-1638.
32. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute 2003 Aug 20, 95(16):1218-1226.
33. Garofalo C., Surmacz E. Leptin and cancer. Journal of Cellular Physiology 2006 Apr, 207(1):12-22.
34. Barone I., Catalano S., Gelsomino L., Marsico S., Giordano C., Panza S., et al. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Research 2012 Mar 15, 72(6):1416-1427.
35. D'Esposito V., Passaretti F., Hammarstedt A., Liguoro D., Terracciano D., Molea G., et al. Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth invitro. Diabetologia 2012 Oct, 55(10):2811-2822.
36. Sisci D., Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. Current Pharmaceutical Design 2007, 13(7):705-717.
37. Wu Y., Zhou B.P. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009 Oct 15, 8(20):3267-3273.
38. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008 Jul 24, 454(7203):436-444.
39. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004 Sep 23, 431(7007):461-466.
40. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999 Aug 6, 98(3):295-303.
41. Hemkens L.G., Grouven U., Bender R., Gunster C., Gutschmidt S., Selke G.W., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009 Sep, 52(9):1732-1744.
42. Zib I., Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes, Obesity & Metabolism 2006 Nov, 8(6):611-620.
43. Smith U., Gale E.A. Does diabetes therapy influence the risk of cancer?. Diabetologia 2009 Sep, 52(9):1699-1708.
44. Agin A., Jeandidier N., Gasser F., Grucker D., Sapin R. Glargine blood biotransformation: invitro appraisal with human insulin immunoassay. Diabetes & Metabolism 2007 Jun, 33(3):205-212.
45. Monami M., Balzi D., Lamanna C., Barchielli A., Masotti G., Buiatti E., et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metabolism Research and Reviews 2007 Sep, 23(6):479-484.
46. Singh S., Singh P.P., Singh A.G., Murad M.H., McWilliams R.R., Chari S.T. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. The American Journal of Gastroenterology 2013 Feb 12.
47. Vangoitsenhoven R., Mathieu C., Van der Schueren B. GLP1 and cancer: friend or foe?. Endocrine-Related Cancer 2012 Oct, 19(5):F77-F88.
48. Labuzek K., Kozlowski M., Szkudlapski D., Sikorska P., Kozlowska M., Okopien B. Incretin-based therapies in the treatment of type 2 diabetes-more than meets the eye?. European Journal of Internal Medicine 2013 Apr, 24(3):207-212.
49. Landman G.W., Kleefstra N., van Hateren K.J., Groenier K.H., Gans R.O., Bilo H.J. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010 Feb, 33(2):322-326.
50. Suissa S., Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012 Dec, 35(12):2665-2673.
51. Guppy A., Jamal-Hanjani M., Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncology 2011 Jun, 7(6):727-736.
52. Bosetti C., Rosato V., Buniato D., Zambon A., La Vecchia C., Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013, 18(2):148-156.
53. Ferwana M., Firwana B., Hasan R., Al-Mallah M.H., Kim S., Montori V.M., et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Medicine 2013 Jan 28.
54. Reilly M.L., Schillie S.F., Smith E., Poissant T., Vonderwahl C.W., Gerard K., et al. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus. Journal of Diabetes Science and Technology 2012 Jul, 6(4):858-866.
55. Festi D., Dormi A., Capodicasa S., Staniscia T., Attili A.F., Loria P., et al. Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World Journal of Gastroenterology 2008 Sep 14, 14(34):5282-5289.
56. Weiderpass E., Gridley G., Persson I., Nyren O., Ekbom A., Adami H.O. Risk of endometrial and breast cancer in patients with diabetes mellitus. International Journal of Cancer Journal International du Cancer 1997 May 2, 71(3):360-363.
57. Lee J.Y., Jeon I., Kim J.W., Song Y.S., Yoon J.M., Park S.M. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. International Journal of Gynecological Cancer 2013 Mar, 23(3):402-412.
58. Wong P., Weiner M.G., Hwang W.T., Yang Y.X. Insulin therapy and colorectal adenomas in patients with diabetes mellitus. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2012 Oct, 21(10):1833-1840.
59. Bao C., Yang X., Xu W., Luo H., Xu Z., Su C., et al. Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. Journal of Diabetes and Its Complications 2013 Feb 20.
60. Newton C.C., Gapstur S.M., Campbell P.T., Jacobs E.J. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. International Journal of Cancer Journal International du Cancer 2013 May 1, 132(9):2186-2191.
61. Sipahi I., Debanne S.M., Rowland D.Y., Simon D.I., Fang J.C. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. The Lancet Oncology 2010 Jul, 11(7):627-636.
62. Frayling T.M., Colhoun H., Florez J.C. A genetic link between type 2 diabetes and prostate cancer. Diabetologia 2008 Oct, 51(10):1757-1760.
63. Emerging Risk Factors C, Seshasai S.R., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. The New England Journal of Medicine 2011 Mar 3, 364(9):829-841.
64. Kent D., D'Eramo Melkus G., Stuart P.M., McKoy J.M., Urbanski P., Boren S.A., et al. Reducing the risks of diabetes complications through diabetes self-management education and support. Population Health Management 2013 Feb 13.